홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
RNAZ
#4268
TransCode Therapeutics, Inc. Common Stock
9.830
0
USD
+0.31%
부문:
헬스케어
베이스:
USD
수익 통화:
USD
일일 변동 비율
년간 변동
일일 변동
+0.31%
월간 변동
+3.39%
6달 변화
+3.39%
년간 변동율
+3.39%
이전 종가
9.800
0
Open
9.750
0
Bid
9.830
0
Ask
9.833
0
Low
9.750
0
High
9.830
0
양
9
마켓
주식
헬스케어
RNAZ
Open full chart
Financials
Overview
성명
Statistics
Quarterly
Annual
Value
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
17.46
21.41
6 285.77
833.62 K
—
Valuation ratios
Enterprise value
—
—
—
—
—
Price to earnings ratio
—
—
—
—
—
Price to sales ratio
—
—
—
—
—
Price to cash flow ratio
—
—
—
—
—
Price to book ratio
—
—
—
—
—
Enterprise value to EBITDA ratio
—
—
—
—
—
Profitability ratios
Return on assets %
-0.3
-2.31
-3.59
-2.3
-1.34
Return on equity %
-0.34
-5.42
-11.3
8.3
0.01
Return on invested capital %
-10.47 K
-33.53 K
-11.4 K
-23.65 K
-38.24 K
Gross margin %
100
—
—
100
400
Operating margin %
199.58 K
—
—
27.69 K
32.55 K
EBITDA margin %
—
—
—
—
—
Net margin %
222.04 K
—
—
29.62 K
-22.94 K
Liquidity ratios
Quick ratio
—
—
—
—
—
Current ratio
8.97
1.7
1.28
2.56
14.62
Inventory turnover
—
—
—
—
—
Asset turnover
-0
—
—
-0.01
0.03
Solvency ratios
Debt to assets ratio
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
Per share metrics
Operating cash flow per share
-462.06 K
899.99 K
-93.3 K
1 045.73
1 874.85
EBIT per share
—
—
—
—
—
EBITDA per share
—
—
—
—
—
Total debt per share
—
—
—
—
—
Cash per share
1.83 M
284.81 K
14.45 K
456.03
535.65
Net current asset value per share
1.99 M
420.34 K
23 K
557.72
649.03
Tangible book value per share
1.79 M
184.59 K
8 469.62
-158.73
-89.89
Working capital per share
1.77 M
172.71 K
4 980.39
339.78
411.09
Book value per share
1.79 M
184.59 K
8 469.62
-158.73
-89.89
뉴스
TransCode, 방광암 치료 플랫폼 기술 도입 계약 체결
TransCode licenses bladder cancer therapy platform from Unleash
TransCode Therapeutics, IND 수정안 제출 후 주가 급등
트랜스코드 테라퓨틱스, 뇌종양 연구 발표 후 주가 급등
TransCode Therapeutics stock soars after promising glioblastoma study
TransCode Therapeutics appoints Jack E. Stover to board of directors
암 치료제 2a상 임상시험 예정: TransCode, Quantum Leap 협력
TransCode and Quantum Leap to test cancer therapy in phase 2a trial
TransCode Therapeutics appoints Michel Janicot as development officer
트랜스코드 테라퓨틱스, 주주 승인 후 우선주 조건 변경
Transcode Therapeutics amends preferred stock terms following shareholder approval
TransCode reports positive safety data from TTX-MC138 phase 1a trial